1. Home
  2. BMBL vs OMER Comparison

BMBL vs OMER Comparison

Compare BMBL & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bumble Inc.

BMBL

Bumble Inc.

N/A

Current Price

$2.99

Market Cap

345.0M

Sector

Technology

ML Signal

N/A

Logo Omeros Corporation

OMER

Omeros Corporation

N/A

Current Price

$11.44

Market Cap

821.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BMBL
OMER
Founded
2014
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
345.0M
821.7M
IPO Year
2021
2008

Fundamental Metrics

Financial Performance
Metric
BMBL
OMER
Price
$2.99
$11.44
Analyst Decision
Hold
Strong Buy
Analyst Count
12
5
Target Price
$4.65
$32.50
AVG Volume (30 Days)
2.8M
751.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,071,643,000.00
$29,868,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
1.88
N/A
52 Week Low
$2.61
$2.95
52 Week High
$8.63
$17.65

Technical Indicators

Market Signals
Indicator
BMBL
OMER
Relative Strength Index (RSI) 45.94 44.57
Support Level $2.61 $11.09
Resistance Level $3.85 $11.90
Average True Range (ATR) 0.19 0.50
MACD 0.04 -0.01
Stochastic Oscillator 63.41 21.74

Price Performance

Historical Comparison
BMBL
OMER

About BMBL Bumble Inc.

Bumble Inc is engaged in offering online dating services. The platform enables people to connect and build healthy and equitable relationships on their own terms. The company operates two apps, Bumble and Badoo, where users come every month to discover new people and connect. The company Operates in USA and also Internationally such as United Kingdom, Czech Republic, and others with maximum of revenue from Other Countries.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: